"We are deeply concerned about the Japanese pricing rule, which drastically cuts down the drug price simply by the amount of sales. It is crucial for pharmaceutical companies to be rewarded adequately for innovation, not only to further strengthen the entire Japanese pharmaceutical industry but also for the benefit of Japanese health care. Our goal is to countermeasure these issues by developing innovative drugs."
Koko Harada, head of media relations, Chugai Pharmaceutical Co. Ltd., which faces the prospects of slowing drug sales growth under the Japanese government's plan
"We can get a vaccine candidate ready for phase I by the end of the summer and start the trial by the end of the year. But I can't predict it will be effective, so I can't say when a vaccine will be available for use."
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaking at the AAAS meeting
"It's exponential math, which even for a company like us is not doable."
Paul Biondi, senior vice president, head of business development, Bristol-Myers Squibb Co. on the "combinatorial problem" of testing multiple combinations of cancer drugs and immunotherapies, during a session at the recent BIO CEO & Investor Conference
"I was assuming when we went into the meeting [with the FDA] that we would discuss four or five points, which wouldn't take a full hour, and we'd get up and leave because we didn't like the responses we got. But I found the meeting to be far more collegial than I expected."
Joseph Podolski, president and CEO, Repros Therapeutics Inc., relating during a conference call with analysts the company's meeting with FDA officials to discuss the path forward for enclomiphene